David R Gandara

Title(s)Professor, MED: Int Med Hematology/Oncology
SchoolSchool of Medicine
AddressCancer Center
CA 95817
vCardDownload vCard
    Other Positions
    Title(s)Professor Emeritus, MED: Int Med Hematology/Oncology


    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Oct 09. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. PMID: 39385035.
      View in: PubMed   Mentions:    Fields:    
    2. Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors. Crit Rev Oncol Hematol. 2024 Nov; 203:104483. Reduzzi C, Nicolo' E, Singhal S, Venetis K, Ortega-Franco A, de Miguel-Perez D, Dipasquale A, Gouda MA, Saldanha EF, Kasi PM, Jantus-Lewintre E, Fusco N, Malapelle U, Gandara DR, Rolfo C, Serrano MJ, Cristofanilli M, International Society of Liquid Biopsy (ISLB). PMID: 39159706.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). J Thorac Oncol. 2024 Aug 05. Kozono D, Hua X, Wu MC, Tolba KA, Waqar SN, Dragnev KH, Cheng H, Hirsch FR, Mack PC, Gray JE, Kelly K, Borghaei H, Herbst RS, Gandara DR, Redman MW. PMID: 39111731.
      View in: PubMed   Mentions:    Fields:    
    4. Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study. JTO Clin Res Rep. 2024 Oct; 5(10):100706. Riess JW, Lara MS, Lopez de Rodas M, Luxardi G, Herbert S, Shimoda M, Kelly K, Meerlev A, Moore E, Beckett L, Monjazeb A, Schalper K, Maverakis E, Gandara DR. PMID: 39318388; PMCID: PMC11420451.
      View in: PubMed   Mentions:
    5. Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2024 Sep; 25(6):e252-e261.e4. Gandara DR, Subramanian J, Santos ES, Brody Y, Sela I, Elon Y, Harel M, Reiner-Benaim A, Lahav C, McGregor K. PMID: 39034168.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. CNS Antitumor Activity of Amivantamab With Osimertinib in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer With Acquired Mesenchymal-Epithelial Transition Amplification Resistance Mechanism: A Case Report. JCO Precis Oncol. 2024 Apr; 8:e2300677. Al-Obeidi E, Kelly K, Gandara DR, Riess JW. PMID: 38603654.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer. 2024 May; 202:114024. Hertz DL, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, Gandara D, Stahl M, Monk BJ, Jaehde U, Beumer JH. PMID: 38513383; PMCID: PMC11053297.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer. JCO Precis Oncol. 2024 Mar; 8:e2300555. Christopoulos P, Harel M, McGregor K, Brody Y, Puzanov I, Bar J, Elon Y, Sela I, Yellin B, Lahav C, Raveh S, Reiner-Benaim A, Reinmuth N, Nechushtan H, Farrugia D, Bustinza-Linares E, Lou Y, Leibowitz R, Kamer I, Zer Kuch A, Moskovitz M, Levy-Barda A, Koch I, Lotem M, Katzenelson R, Agbarya A, Price G, Cheley H, Abu-Amna M, Geldart T, Gottfried M, Tepper E, Polychronis A, Wolf I, Dicker AP, Carbone DP, Gandara DR. PMID: 38513170; PMCID: PMC10965206.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Mapping EGFR Exon 20 Resistance Mutations: An Intricate Landscape. J Thorac Oncol. 2024 01; 19(1):10-12. Singhal S, Gandara D, Riess JW. PMID: 38185508.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 03; 19(3):500-506. Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. PMID: 38012986.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042). Clin Cancer Res. 2023 09 15; 29(18):3641-3649. Gadgeel SM, Miao J, Riess JW, Moon J, Mack PC, Gerstner GJ, Burns TF, Taj A, Akerley WL, Dragnev KH, Laudi N, Redman MW, Gray JE, Gandara DR, Kelly K. PMID: 37233987; PMCID: PMC10526968.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    12. Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). JCO Precis Oncol. 2023 09; 7:e2300218. Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar SN, Edelman MJ, Sigal EV, Adam SJ, Malik S, Blanke CD, LeBlanc ML, Kelly K, Gray JE, Redman MW. PMID: 37677122; PMCID: PMC10581630.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes. JCO Precis Oncol. 2023 09; 7:e2300118. Kasi PM, Bucheit LA, Liao J, Starr J, Barata P, Klempner SJ, Gandara D, Shergill A, Madeira da Silva L, Weipert C, Zhang N, Pretz C, Hardin A, Kiedrowski LA, Odegaard JI. PMID: 37769226.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    14. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 05 10; 41(14):2458-2466. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. PMID: 37146426.
      View in: PubMed   Mentions: 5     Fields:    Translation:CTClinical Trials
    15. Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. J Natl Cancer Inst. 2023 04 11; 115(4):437-446. Unger JM, Qian L, Redman MW, Tavernier SS, Minasian L, Sigal EV, Papadimitrakopoulou VA, Leblanc M, Cleeland CS, Dzingle SA, Summers TJ, Chao H, Madhusudhana S, Villaruz L, Crawford J, Gray JE, Kelly KL, Gandara DR, Bazhenova L, Herbst RS, Gettinger SN, Moinpour CM. PMID: 36625510; PMCID: PMC10086628.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    16. Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2023 06; 37(3):475-487. Al-Obeidi E, Riess JW, Malapelle U, Rolfo C, Gandara DR. PMID: 37024388.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. 27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study. Clin Lung Cancer. 2023 03; 24(2):137-144. Saltman DL, Varga MG, Nielsen TJ, Croteau NS, Lockyer HM, Jain AL, Vidal GA, Hout DR, Schweitzer BL, Seitz RS, Ross DT, Gandara DR. PMID: 36564297.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    18. Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC. JTO Clin Res Rep. 2022 Dec; 3(12):100436. Lara MS, Gubens MA, Bacaltos B, Daran L, Lim SL, Li T, Gandara DR, Bivona TG, Riess JW, Blakely CM. PMID: 36545322; PMCID: PMC9761844.
      View in: PubMed   Mentions: 4  
    19. A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer. Cancer Res. 2022 11 15; 82(22):4126-4138. Woo XY, Srivastava A, Mack PC, Graber JH, Sanderson BJ, Lloyd MW, Chen M, Domanskyi S, Gandour-Edwards R, Tsai RA, Keck J, Cheng M, Bundy M, Jocoy EL, Riess JW, Holland W, Grubb SC, Peterson JG, Stafford GA, Paisie C, Neuhauser SB, Karuturi RKM, George J, Simons AK, Chavaree M, Tepper CG, Goodwin N, Airhart SD, Lara PN, Openshaw TH, Liu ET, Gandara DR, Bult CJ. PMID: 36069866; PMCID: PMC9664138.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    20. Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations. Cancers (Basel). 2022 Sep 01; 14(17). Kurzrock R, Aggarwal C, Weipert C, Kiedrowski L, Riess J, Lenz HJ, Gandara D. PMID: 36077815; PMCID: PMC9454642.
      View in: PubMed   Mentions: 4  
    21. Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). Clin Cancer Res. 2022 09 01; 28(17):3752-3760. Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, Melnick MA, Walther Z, Hirsch FR, Politi K, Kelly K, Gandara DR. PMID: 35713632; PMCID: PMC9444942.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    22. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022 09; 28(9):1831-1839. Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. PMID: 35995953; PMCID: PMC9499854.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    23. The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations. JCO Glob Oncol. 2022 08; 8:e2200123. Caglevic C, Rolfo C, Gil-Bazo I, Cardona A, Sapunar J, Hirsch FR, Gandara DR, Morgan G, Novello S, Garassino MC, Mountzios G, Leighl NB, Bretel D, Arrieta O, Addeo A, Liu SV, Corrales L, Subbiah V, Aboitiz F, Villarroel-Espindola F, Reyes-Cosmelli F, Morales R, Mahave M, Raez L, Alatorre J, Santos E, Ubillos L, Tan DSW, Zielinski C. PMID: 35994695; PMCID: PMC9470147.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    24. A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer. Cancer Chemother Pharmacol. 2022 09; 90(3):217-228. Chen JA, Huynh JC, Wu CY, Yu AM, Matsukuma K, Semrad TJ, Gandara DR, Li T, Riess JW, Tam K, Mack PC, Martinez A, Mahaffey N, Kelly KL, Kim EJ. PMID: 35907014; PMCID: PMC9402746.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    25. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A. J Clin Oncol. 2022 07 20; 40(21):2295-2306. Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, Al Baghdadi T, Hines S, Everhart L, Highleyman L, Papadimitrakopoulou V, Waqar SN, Patel JD, Gray JE, Gandara DR, Kelly K, Herbst RS. PMID: 35658002; PMCID: PMC9287284.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    26. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. BMC Cancer. 2022 Apr 14; 22(1):407. Ranganath H, Jain AL, Smith JR, Ryder J, Chaudry A, Miller E, Hare F, Valasareddy P, Seitz RS, Hout DR, Varga MG, Schweitzer BL, Nielsen TJ, Mullins J, Ross DT, Gandara DR, Vidal GA. PMID: 35421940; PMCID: PMC9008990.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    27. ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy. JCO Precis Oncol. 2021 11; 5:827-838. Zou W, Yaung SJ, Fuhlbrück F, Ballinger M, Peters E, Palma JF, Shames DS, Gandara D, Jiang Y, Patil NS. PMID: 34994614.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    28. Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Rev Mol Diagn. 2021 Nov; 21(11):1165-1178. Malapelle U, Pisapia P, Addeo A, Arrieta O, Bellosillo B, Cardona AF, Cristofanilli M, De Miguel-Perez D, Denninghoff V, Durán I, Jantus-Lewintre E, Nuzzo PV, O'Byrne K, Pauwels P, Pickering EM, Raez LE, Russo A, Serrano MJ, Gandara DR, Troncone G, Rolfo C. PMID: 34570988.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    29. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clin Lung Cancer. 2022 01; 23(1):60-71. Hirsch FR, Redman MW, Moon J, Agustoni F, Herbst RS, Semrad TJ, Varella-Garcia M, Rivard CJ, Kelly K, Gandara DR, Mack PC. PMID: 34753703; PMCID: PMC8766941.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    30. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer. 2022 02; 126(3):514-520. Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. PMID: 34480094; PMCID: PMC8811064.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    31. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Sep 01; 7(9):1368-1377. Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. PMID: 34264316; PMCID: PMC8283667.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCellsCTClinical Trials
    32. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). J Immunother Cancer. 2021 08; 9(8). Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, Herbst RS, Papadimitrakopoulou VA, Kelly K, Gandara DR. PMID: 34429332; PMCID: PMC8386207.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    33. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021 10; 16(10):1647-1662. Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, Leighl N, Malapelle U, Mok T, Peled N, Raez LE, Sequist L, Sholl L, Swanton C, Abbosh C, Tan D, Wakelee H, Wistuba I, Bunn R, Freeman-Daily J, Wynes M, Belani C, Mitsudomi T, Gandara D. PMID: 34246791.
      View in: PubMed   Mentions: 184     Fields:    Translation:Humans
    34. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clin Lung Cancer. 2022 01; 23(1):21-33. Gadgeel S, Hirsch FR, Kerr K, Barlesi F, Park K, Rittmeyer A, Zou W, Bhatia N, Koeppen H, Paul SM, Shames D, Yi J, Matheny C, Ballinger M, McCleland M, Gandara DR. PMID: 34226144.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    35. Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clin Lung Cancer. 2021 11; 22(6):541-548. Riess JW, Reckamp KL, Frankel P, Longmate J, Kelly KA, Gandara DR, Weipert CM, Raymond VM, Keer HN, Mack PC, Newman EM, Lara PN. PMID: 34140248; PMCID: PMC9239707.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    36. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2021 08; 88(2):335-341. Semrad TJ, Kim EJ, Gong IY, Li T, Christensen S, Arora M, Riess JW, Gandara DR, Kelly K. PMID: 33993383; PMCID: PMC8259450.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    37. Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). JCO Oncol Pract. 2021 11; 17(11):e1821-e1829. Roth JA, Trivedi MS, Gray SW, Patrick DL, Delaney DM, Watabayashi K, Litwin P, Shah P, Crew KD, Yee M, Redman MW, Unger JM, Papadimitrakopoulou V, Johnson J, Kelly K, Gandara D, Herbst RS, Hershman DL, Ramsey SD. PMID: 33797955; PMCID: PMC9810137.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    38. Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a Model. Clin Lung Cancer. 2021 05; 22(3):153-155. Riess JW, Rolfo C, Gandara DR. PMID: 33879399.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. J Immunother Cancer. 2021 03; 9(3). Gandara D, Reck M, Moro-Sibilot D, Mazieres J, Gadgeel S, Morris S, Cardona A, Mendus D, Ballinger M, Rittmeyer A, Peters S. PMID: 33737340; PMCID: PMC7978260.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    40. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811). Clin Lung Cancer. 2021 07; 22(4):313-323.e1. Argiris A, Miao J, Cristea MC, Chen AM, Sands JM, Decker RH, Gettinger SN, Daly ME, Faller BA, Albain KS, Yanagihara RH, Garland LL, Byers LA, Wang D, Koczywas M, Redman MW, Kelly K, Gandara DR. PMID: 33745865; PMCID: PMC8562492.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    41. Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. J Thorac Oncol. 2021 06; 16(6):960-967. Steuer CE, Jegede OA, Dahlberg SE, Wakelee HA, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Butts CA, Ramalingam SS, Schiller JH, ECOG-ACRIN 1505 Investigators. PMID: 33539971; PMCID: PMC8383783.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    42. Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021; 1. McCoach CE, Yu A, Gandara DR, Riess JW, Vang DP, Li T, Lara PN, Gubens M, Lara F, Mack PC, Beckett LA, Kelly K. PMID: 34036220; PMCID: PMC8140807.
      View in: PubMed   Mentions: 12     Fields:    
    43. Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. Clin Lung Cancer. 2021 05; 22(3):187-194.e1. Owonikoko TK, Redman MW, Byers LA, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Al Baghdadi T, Lara P, Miao J, Kelly K, Ramalingam SS, Herbst RS, Papadimitrakopoulou V, Gandara DR. PMID: 33583720; PMCID: PMC8637652.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    44. A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemother Pharmacol. 2021 04; 87(4):525-532. Thomas JS, El-Khoueiry AB, Maurer BJ, Groshen S, Pinski JK, Cobos E, Gandara DR, Lenz HJ, Kang MH, Reynolds CP, Newman EM. PMID: 33423090; PMCID: PMC8058950.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    45. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Invest New Drugs. 2021 06; 39(3):812-820. Quinn DI, Tsao-Wei DD, Twardowski P, Aparicio AM, Frankel P, Chatta G, Wright JJ, Groshen SG, Khoo S, Lenz HJ, Lara PN, Gandara DR, Newman E. PMID: 33409898.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    46. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). Clin Lung Cancer. 2021 05; 22(3):178-186. Borghaei H, Redman MW, Kelly K, Waqar SN, Robert F, Kiefer GJ, Stella PJ, Minichiello K, Gandara DR, Herbst RS, Papadimitrakopoulou VA. PMID: 33358401; PMCID: PMC8686189.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    47. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. J Thorac Oncol. 2021 01; 16(1):140-150. Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, Cortinovis DL, Barlesi F, Yu W, Matheny C, Ballinger M, Park K. PMID: 33166718.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    48. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020 12; 21(12):1589-1601. Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. PMID: 33125909; PMCID: PMC8109255.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    49. Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. Clin Lung Cancer. 2021 01; 22(1):67-70. Riess JW, Frankel P, Shackelford D, Dunphy M, Badawi RD, Nardo L, Cherry SR, Lanza I, Reid J, Gonsalves WI, Kunos C, Gandara DR, Lara PN, Newman E, Paik PK. PMID: 33229301; PMCID: PMC7834952.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    50. A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clin Lung Cancer. 2021 05; 22(3):170-177. Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. PMID: 33221175; PMCID: PMC8044254.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    51. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403. J Clin Oncol. 2020 12 01; 38(34):4076-4085. Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR. PMID: 33021871; PMCID: PMC7768342.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    52. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nat Rev Clin Oncol. 2021 01; 18(1):56-62. Aggarwal C, Rolfo CD, Oxnard GR, Gray JE, Sholl LM, Gandara DR. PMID: 32918064.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    53. Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. J Thorac Oncol. 2020 10; 15(10):1611-1623. Negrao MV, Raymond VM, Lanman RB, Robichaux JP, He J, Nilsson MB, Ng PKS, Amador BE, Roarty EB, Nagy RJ, Banks KC, Zhu VW, Ng C, Chae YK, Clarke JM, Crawford JA, Meric-Bernstam F, Ignatius Ou SH, Gandara DR, Heymach JV, Bivona TG, McCoach CE. PMID: 32540409; PMCID: PMC7529990.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    54. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases. Cancer. 2020 07 15; 126(14):3219-3228. Mack PC, Banks KC, Espenschied CR, Burich RA, Zill OA, Lee CE, Riess JW, Mortimer SA, Talasaz A, Lanman RB, Gandara DR. PMID: 32365229; PMCID: PMC7383626.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCells
    55. Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020 05; 85(5):979-993. Coyne GO', Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, Nieva JJ, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE, Kinders RJ, Piekarz RL, Kummar S, Chen AP, Doroshow JH. PMID: 32314030; PMCID: PMC7188725.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    56. CT Volumetry and Basic Texture Analysis as Surrogate Markers in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):225-231. Owen B, Gandara D, Kelly K, Moore E, Shelton D, Knollmann F. PMID: 31699509.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    57. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemother Pharmacol. 2019 12; 84(6):1289-1301. Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS. PMID: 31549216; PMCID: PMC7825275.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    58. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Cancer Chemother Pharmacol. 2019 12; 84(6):1201-1208. Luu T, Frankel P, Beumer JH, Lim D, Cristea M, Appleman LJ, Lenz HJ, Gandara DR, Kiesel BF, Piekarz RL, Newman EM. PMID: 31522242; PMCID: PMC6821594.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    59. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol. 2019 10 01; 37(28):2537-2547. Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. PMID: 31386610; PMCID: PMC7001793.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    60. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019 07 23; 3(14):2237-2243. Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR. PMID: 31337605; PMCID: PMC6650731.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    61. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1853-1859. Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. PMID: 31302234; PMCID: PMC6764876.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    62. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies. Clin Lung Cancer. 2019 11; 20(6):451-460.e5. Schulz C, Gandara D, Berardo CG, Rosenthal R, Foo J, Morel C, Ballinger M, Watkins C, Chu P. PMID: 31375454.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    63. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol. 2019 10; 14(10):1847-1852. Aggarwal C, Redman MW, Lara PN, Borghaei H, Hoffman P, Bradley JD, Newman AJ, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR. PMID: 31195180; PMCID: PMC6901020.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    64. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Invest New Drugs. 2019 08; 37(4):755-762. Xie H, Yin J, Shah MH, Menefee ME, Bible KC, Reidy-Lagunes D, Kane MA, Quinn DI, Gandara DR, Erlichman C, Adjei AA. PMID: 31172443; PMCID: PMC7515770.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    65. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019 10; 14(10):1839-1846. Langer CJ, Redman MW, Wade JL, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA. PMID: 31158500; PMCID: PMC7017958.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    66. Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. Am Soc Clin Oncol Educ Book. 2019 01; 39:531-542. Pennell NA, Arcila ME, Gandara DR, West H. PMID: 31099633.
      View in: PubMed   Mentions: 128     Fields:    Translation:Humans
    67. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303). Front Oncol. 2019; 9:132. Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN. PMID: 30915273; PMCID: PMC6421302.
      View in: PubMed   Mentions: 27  
    68. Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048. Kidney Cancer. 2019 Feb 05; 3(1):51-61. Semrad TJ, Groshen S, Luo C, Pal S, Vaishampayan U, Joshi M, Quinn DI, Mack PC, Gandara DR, Lara PN. PMID: 30854497; PMCID: PMC6400131.
      View in: PubMed   Mentions: 4  
    69. EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade. Clin Lung Cancer. 2019 05; 20(3):e238-e241. Narayanan A, Knollmann FD, Walby JAS, Lim S, Gandara DR, Riess JW. PMID: 30679078.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    70. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. Eur J Cancer. 2019 01; 107:124-132. von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P, Gandara DR, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K. PMID: 30562710.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    71. Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death Differ. 2018 11; 25(11):1885-1904. Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, Manley JL, Mikoshiba K, Onuchic JN, Pass HI, Pinton P, Prives C, Rothman N, Sebti SM, Turkson J, Wu X, Yang H, Yu H, Melino G. PMID: 30323273; PMCID: PMC6219489.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    72. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. J Thorac Oncol. 2019 01; 14(1):25-36. Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR. PMID: 30253973; PMCID: PMC6309634.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    73. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. J Thorac Oncol. 2018 12; 13(12):1906-1918. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L. PMID: 30217492.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    74. In Search of an Oncogene Driver for Squamous Lung Cancer. JAMA Oncol. 2018 09 01; 4(9):1197-1198. Gandara DR, Riess JW, Lara PN. PMID: 29902311.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    75. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 10; 82(4):723-732. Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM. PMID: 30128950; PMCID: PMC6342617.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    76. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018 09; 24(9):1441-1448. Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, Cummings CA, Hegde PS, Sandler A, Ballinger M, Fabrizio D, Mok T, Shames DS. PMID: 30082870.
      View in: PubMed   Mentions: 565     Fields:    Translation:Humans
    77. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018 08 01; 29(8):1701-1709. Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. PMID: 29905778; PMCID: PMC6128180.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    78. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol. 2018 10; 13(10):1560-1568. Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB. PMID: 29981927; PMCID: PMC6764748.
      View in: PubMed   Mentions: 99     Fields:    Translation:Humans
    79. Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst. 2018 07 01; 110(7):734-742. Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB. PMID: 29346580; PMCID: PMC6037104.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    80. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018 09; 13(9):1248-1268. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. PMID: 29885479.
      View in: PubMed   Mentions: 266     Fields:    Translation:Humans
    81. CT perfusion imaging of lung cancer: benefit of motion correction for blood flow estimates. Eur Radiol. 2018 Dec; 28(12):5069-5075. Chu LL, Knebel RJ, Shay AD, Santos J, Badawi RD, Gandara DR, Knollmann FD. PMID: 29869174.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    82. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018 08 01; 24(15):3528-3538. Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, Gandara DR, Mack PC, Odegaard JI, Nagy RJ, Baca AM, Eltoukhy H, Chudova DI, Lanman RB, Talasaz A. PMID: 29776953.
      View in: PubMed   Mentions: 171     Fields:    Translation:Humans
    83. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 08; 13(8):1156-1170. Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F. PMID: 29777823.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansCTClinical Trials
    84. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. Clin Cancer Res. 2018 07 15; 24(14):3292-3298. Claret L, Jin JY, Ferté C, Winter H, Girish S, Stroh M, He P, Ballinger M, Sandler A, Joshi A, Rittmeyer A, Gandara D, Soria JC, Bruno R. PMID: 29685883.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    85. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer. 2018 07; 19(4):331-339. Hirsch FR, Kerr KM, Bunn PA, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. PMID: 29773328.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    86. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 05; 81(5):957-963. El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR. PMID: 29520435; PMCID: PMC6330274.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    87. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther. 2018 05; 17(5):885-896. Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE. PMID: 29483211; PMCID: PMC5932243.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    88. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2018 02; 13(2):165-183. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. PMID: 29175116.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    89. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 01; 19(1):101-114. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. PMID: 29169877; PMCID: PMC5847342.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    90. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 12; 18(12):1610-1623. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH, ECOG-ACRIN. PMID: 29129443; PMCID: PMC5789803.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    91. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. PMID: 29106415; PMCID: PMC5709185.
      View in: PubMed   Mentions: 258     Fields:    Translation:HumansCells
    92. Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. Lung Cancer. 2017 10; 112:165-168. Lara JD, Brunson A, Riess JW, Kelly K, Lara PN, Gandara DR. PMID: 29191590.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    93. American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions. J Glob Oncol. 2018 09; 4:1-8. Hortobagyi GN, Pyle D, Cazap EL, El Saghir NS, Shulman LN, Lyman GH, Schnipper LE, Adebamowo CA, Gandara DR, Vose J, Wong SL, Yu P. PMID: 30241187; PMCID: PMC6180769.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    94. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer. 2018 01; 19(1):84-92. West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR. PMID: 28801183; PMCID: PMC5748264.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    95. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. Clin Lung Cancer. 2018 01; 19(1):35-41. Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C. PMID: 28757336.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    96. An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. Clin Lung Cancer. 2018 01; 19(1):42-50. Melosky B, Popat S, Gandara DR. PMID: 28668205.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    97. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol. 2017 08; 12(8):1299-1308. Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K. PMID: 28599887; PMCID: PMC5690479.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    98. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. PMID: 28579481.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    99. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 01; 23(15):4066-4076. Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN. PMID: 28356425; PMCID: PMC5540749.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    100. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. PMID: 28447912; PMCID: PMC5559893.
      View in: PubMed   Mentions: 153     Fields:    Translation:Humans
    101. Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer. J Thorac Oncol. 2017 07; 12(7):e81-e84. Peled N, Roisman LC, Miron B, Pfeffer R, Lanman RB, Ilouze M, Dvir A, Soussan-Gutman L, Barlesi F, Tarcic G, Edelheit O, Gandara D, Elkabetz Y. PMID: 28286242.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    102. Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma. Carcinogenesis. 2017 03; 38(3):271-280. Fahrmann JF, Grapov DD, Wanichthanarak K, DeFelice BC, Salemi MR, Rom WN, Gandara DR, Phinney BS, Fiehn O, Pass H, Miyamoto S. PMID: 28049629; PMCID: PMC5862279.
      View in: PubMed   Mentions: 33     Fields:    
    103. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treat Res Commun. 2017; 10:21-26. Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara DR, Lara P, Mack PC. PMID: 28736761; PMCID: PMC5519297.
      View in: PubMed   Mentions: 12     Fields:    
    104. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN. PMID: 28082049.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    105. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 01 21; 389(10066):255-265. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group. PMID: 27979383; PMCID: PMC6886121.
      View in: PubMed   Mentions: 2213     Fields:    Translation:HumansCTClinical Trials
    106. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 May; 18(3):281-285. Lara MS, Holland WS, Chinn D, Burich RA, Lara PN, Gandara DR, Kelly K, Mack PC. PMID: 28038979; PMCID: PMC5837026.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    107. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566. Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM, Blumenschein G. PMID: 27876675.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    108. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. J Thorac Oncol. 2017 03; 12(3):477-490. Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, Gandara DR, Date H, Hasegawa S. PMID: 27867002.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    109. Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer. J Clin Oncol. 2016 11 01; 34(31):3717-3718. Riess JW, Lara PN, Gandara DR. PMID: 27601544; PMCID: PMC5477925.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    110. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):60-67. Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN, Gandara DR, Perez-Soler R. PMID: 27919627; PMCID: PMC5497702.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    111. Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival. Clin Proteomics. 2016; 13:31. Fahrmann JF, Grapov D, Phinney BS, Stroble C, DeFelice BC, Rom W, Gandara DR, Zhang Y, Fiehn O, Pass H, Miyamoto S. PMID: 27799870; PMCID: PMC5084393.
      View in: PubMed   Mentions: 23  
    112. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999. Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE. PMID: 27646951; PMCID: PMC5477832.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    113. A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol. 2018 02; 180(3):445-448. Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara PN. PMID: 27650362; PMCID: PMC5360527.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    114. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. J Thorac Oncol. 2016 12; 11(12):2066-2081. Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N. PMID: 27575423.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    115. Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. Clin Lung Cancer. 2017 01; 18(1):5-12. Salahudeen AA, Patel MI, Baas P, Curran WJ, Bradley JD, Gandara DR, Goss GD, Mok TS, Ramalingam SS, Vokes EE, Malik SM, Wakelee HA. PMID: 27473736; PMCID: PMC5361177.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    116. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016 09; 11(9):1411-22. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N. PMID: 27296106.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    117. Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. Clin Lung Cancer. 2017 01; 18(1):e71-e79. Raez LE, Santos ES, Rolfo C, Lopes G, Barrios C, Cardona A, Mas LA, Arrieta O, Richardet E, Vallejos S C, Wistuba I, Gandara D, Hirsch FR. PMID: 27426974.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    118. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):43-49. Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara DR. PMID: 27461773.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    119. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 07; 11(7):946-63. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. PMID: 27229180.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans
    120. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-638. Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. PMID: 27013409.
      View in: PubMed   Mentions: 140     Fields:    Translation:Humans
    121. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs. 2016 06; 34(3):355-63. Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH. PMID: 26996385; PMCID: PMC4860030.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    122. Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials. JAMA Oncol. 2016 Mar; 2(3):300-1. Gandara DR, Redman M, Hirsch FR. PMID: 26720042.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    123. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol. 2016 Apr; 11(4):453-74. Bunn PA, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. PMID: 26829312; PMCID: PMC4836290.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansAnimals
    124. Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer. Cancer Prev Res (Phila). 2016 Apr; 9(4):317-23. Ruhaak LR, Stroble C, Dai J, Barnett M, Taguchi A, Goodman GE, Miyamoto S, Gandara D, Feng Z, Lebrilla CB, Hanash S. PMID: 26813970; PMCID: PMC4818659.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    125. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Mar 20; 34(9):953-62. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PMID: 26811519.
      View in: PubMed   Mentions: 172     Fields:    Translation:HumansCTClinical Trials
    126. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9. Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G. PMID: 26802155; PMCID: PMC4803455.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    127. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar; 11(3):420-5. Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR. PMID: 26725184; PMCID: PMC4775366.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    128. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 15; 21(24):5439-44. Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE. PMID: 26672084; PMCID: PMC4683399.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    129. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-8.e1-2. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR. PMID: 26498504; PMCID: PMC4789142.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    130. Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Oct; 10(10):1421-9. Chow H, Edelman MJ, Giaccone G, Ramalingam SS, Quill TA, Bowser AD, Mortimer J, Guerra W, Beckett LA, West HL, Lara PN, Gandara DR. PMID: 25719266.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    131. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM. PMID: 26362045; PMCID: PMC4694049.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    132. Lung-MAP--framework, overview, and design principles. Chin Clin Oncol. 2015 Sep; 4(3):36. Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. PMID: 26408303.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    133. Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1716-23. Fahrmann JF, Kim K, DeFelice BC, Taylor SL, Gandara DR, Yoneda KY, Cooke DT, Fiehn O, Kelly K, Miyamoto S. PMID: 26282632; PMCID: PMC4633344.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    134. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. J Clin Oncol. 2015 Nov 20; 33(33):3880-6. Wikoff WR, Hanash S, DeFelice B, Miyamoto S, Barnett M, Zhao Y, Goodman G, Feng Z, Gandara D, Fiehn O, Taguchi A. PMID: 26282655; PMCID: PMC4652011.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    135. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One. 2015; 10(8):e0134346. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. PMID: 26270481; PMCID: PMC4535951.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    136. Modern Methods for Delineating Metagenomic Complexity. Cell Syst. 2015 Jul 29; 1(1):6-7. Afshinnekoo E, Meydan C, Chowdhury S, Jaroudi D, Boyer C, Bernstein N, Maritz JM, Reeves D, Gandara J, Chhangawala S, Ahsanuddin S, Simmons A, Nessel T, Sundaresh B, Pereira E, Jorgensen E, Kolokotronis SO, Kirchberger N, Garcia I, Gandara D, Dhanraj S, Nawrin T, Saletore Y, Alexander N, Vijay P, Hénaff EM, Zumbo P, Walsh M, O'Mullan GD, Tighe S, Dudley JT, Dunaif A, Ennis S, O'Halloran E, Magalhaes TR, Boone B, Jones AL, Muth TR, Paolantonio KS, Alter E, Schadt EE, Garbarino J, Prill RJ, Carlton JM, Levy S, Mason CE. PMID: 27135684.
      View in: PubMed   Mentions: 10     Fields:    
    137. Geospatial Resolution of Human and Bacterial Diversity with City-Scale Metagenomics. Cell Syst. 2015 Jul 29; 1(1):97-97.e3. Afshinnekoo E, Meydan C, Chowdhury S, Jaroudi D, Boyer C, Bernstein N, Maritz JM, Reeves D, Gandara J, Chhangawala S, Ahsanuddin S, Simmons A, Nessel T, Sundaresh B, Pereira E, Jorgensen E, Kolokotronis SO, Kirchberger N, Garcia I, Gandara D, Dhanraj S, Nawrin T, Saletore Y, Alexander N, Vijay P, Hénaff EM, Zumbo P, Walsh M, O'Mullan GD, Tighe S, Dudley JT, Dunaif A, Ennis S, O'Halloran E, Magalhaes TR, Boone B, Jones AL, Muth TR, Paolantonio KS, Alter E, Schadt EE, Garbarino J, Prill RJ, Carlton JM, Levy S, Mason CE. PMID: 27135689.
      View in: PubMed   Mentions: 18     Fields:    
    138. Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap. J Clin Oncol. 2015 Sep 10; 33(26):2839-40. Gandara DR, Lara PN, Mack PC. PMID: 26215942.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    139. EGFR tyrosine kinase inhibitors in squamous cell lung cancer. Lancet Oncol. 2015 Aug; 16(8):872-3. Hirsch FR, Herbst RS, Gandara DR. PMID: 26156654.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    140. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol. 2015 Jul; 10(7):974-84. Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. PMID: 26134219; PMCID: PMC4618296.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    141. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106. Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. PMID: 26134227; PMCID: PMC4493926.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    142. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. PMID: 26106072; PMCID: PMC4592395.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    143. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015 May 15; 21(10):2236-43. Gandara DR, Hammerman PS, Sos ML, Lara PN, Hirsch FR. PMID: 25979930; PMCID: PMC4862209.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansAnimals
    144. Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer". J Thorac Oncol. 2015 May; 10(5):e36. Lara PN, Gandara DR, Redman MW. PMID: 25898968.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    145. Innovative Clinical Trials: The LUNG-MAP Study. Clin Pharmacol Ther. 2015 May; 97(5):488-91. Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. PMID: 25676724.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    146. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer. 2015 May 12; 112(10):1644-51. Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH, Wilczynski S, Christensen S, Gandara DR, Chow WA. PMID: 25897676; PMCID: PMC4430716.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    147. Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. Metabolites. 2015 Apr 09; 5(2):192-210. Miyamoto S, Taylor SL, Barupal DK, Taguchi A, Wohlgemuth G, Wikoff WR, Yoneda KY, Gandara DR, Hanash SM, Kim K, Fiehn O. PMID: 25859693; PMCID: PMC4495369.
      View in: PubMed   Mentions: 36  
    148. Targeting of MEK in lung cancer therapeutics. Lancet Respir Med. 2015 Apr; 3(4):319-27. Heigener DF, Gandara DR, Reck M. PMID: 25801412.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    149. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. PMID: 25838158; PMCID: PMC4586173.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    150. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2480-6. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN. PMID: 25739672; PMCID: PMC4452427.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    151. Geospatial Resolution of Human and Bacterial Diversity with City-Scale Metagenomics. Cell Syst. 2015 Jul 29; 1(1):72-87. Afshinnekoo E, Meydan C, Chowdhury S, Jaroudi D, Boyer C, Bernstein N, Maritz JM, Reeves D, Gandara J, Chhangawala S, Ahsanuddin S, Simmons A, Nessel T, Sundaresh B, Pereira E, Jorgensen E, Kolokotronis SO, Kirchberger N, Garcia I, Gandara D, Dhanraj S, Nawrin T, Saletore Y, Alexander N, Vijay P, Hénaff EM, Zumbo P, Walsh M, O'Mullan GD, Tighe S, Dudley JT, Dunaif A, Ennis S, O'Halloran E, Magalhaes TR, Boone B, Jones AL, Muth TR, Paolantonio KS, Alter E, Schadt EE, Garbarino J, Prill RJ, Carlton JM, Levy S, Mason CE. PMID: 26594662; PMCID: PMC4651444.
      View in: PubMed   Mentions: 145     Fields:    
    152. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015 Mar; 16(3):257-65. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. PMID: 25704439; PMCID: PMC5726228.
      View in: PubMed   Mentions: 709     Fields:    Translation:HumansCellsCTClinical Trials
    153. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 01; 21(7):1514-24. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. PMID: 25680375; PMCID: PMC4654466.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCTClinical Trials
    154. Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. Cancer Prev Res (Phila). 2015 May; 8(5):410-8. Wikoff WR, Grapov D, Fahrmann JF, DeFelice B, Rom WN, Pass HI, Kim K, Nguyen U, Taylor SL, Gandara DR, Kelly K, Fiehn O, Miyamoto S. PMID: 25657018; PMCID: PMC4618700.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    155. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015 Feb; 10(2):387-91. Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR. PMID: 25611229; PMCID: PMC4304604.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    156. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1574-82. Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. PMID: 25589624; PMCID: PMC4383665.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    157. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep; 16(5):340-7. Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. PMID: 25703100; PMCID: PMC4497941.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    158. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR. PMID: 25490004; PMCID: PMC4320001.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    159. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res. 2015 Feb 15; 21(4):739-48. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS. PMID: 25516890; PMCID: PMC4335074.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    160. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 09; 111(12):2268-74. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. PMID: 25349975; PMCID: PMC4264453.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    161. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 2015 Apr; 141(4):615-26. Holland WS, Chinn DC, Lara PN, Gandara DR, Mack PC. PMID: 25323938; PMCID: PMC4562434.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    162. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014 Aug 10; 32(23):2463-70. Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR. PMID: 25002722; PMCID: PMC4121504.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    163. Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg. 2014 Aug; 98(2):402-10. Kernstine KH, Moon J, Kraut MJ, Pisters KM, Sonett JR, Rusch VW, Thomas CR, Waddell TK, Jett JR, Lyss AP, Keller SM, Gandara DR, American College of Surgeons Oncology Group, Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, North Central Cancer Treatment Group, National Cancer Institute of Canada Clinical Trials Group, Southwest Oncology Group. PMID: 24980603; PMCID: PMC4122593.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    164. Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis. Lung Cancer. 2014 Aug; 85(2):264-9. Lara MS, Brunson A, Wun T, Tomlinson B, Qi L, Cress R, Gandara DR, Kelly K. PMID: 24878033.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    165. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer. 2014 Aug 01; 120(15):2343-51. Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, Redman MW, Gandara DR. PMID: 24752945; PMCID: PMC4140446.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    166. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):36-40. Cooke DT, Gandara DR, Goodwin NC, Calhoun RF, Lara PN, Mack PC, David EA. PMID: 24746995.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    167. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol. 2014 Jan; 9(1):18-25. Li T, Maus MK, Desai SJ, Beckett LA, Stephens C, Huang E, Hsiang J, Zeger G, Danenberg KD, Astrow SH, Gandara DR. PMID: 24346090.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    168. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013 Dec; 8(12):1519-28. Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. PMID: 24189513; PMCID: PMC4072123.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    169. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. Lung Cancer. 2014 Feb; 83(2):163-7. Maus MK, Grimminger PP, Mack PC, Astrow SH, Stephens C, Zeger G, Hsiang J, Brabender J, Friedrich M, Alakus H, Hölscher AH, Lara P, Danenberg KD, Lenz HJ, Gandara DR. PMID: 24331409.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    170. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. PMID: 24176733; PMCID: PMC4586161.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    171. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis. 2013 Oct; 5 Suppl 5:S556-64. Lwin Z, Riess JW, Gandara D. PMID: 24163748; PMCID: PMC3804876.
      View in: PubMed   Mentions: 15  
    172. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. PMID: 24013936; PMCID: PMC4562389.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    173. A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. Front Oncol. 2013; 3:219. Chen Y, Moon J, Pandya KJ, Lau DH, Kelly K, Hirsch FR, Gaspar LE, Redman M, Gandara DR. PMID: 24010120; PMCID: PMC3755267.
      View in: PubMed   Mentions: 4  
    174. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013 Sep 20; 31(27):3320-6. Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA. PMID: 23980091; PMCID: PMC3770864.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansCTClinical Trials
    175. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov; 14(6):627-35. Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. PMID: 23910067; PMCID: PMC4122504.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    176. FASTACT-2: but don't act too fast. Lancet Oncol. 2013 Jul; 14(8):684-5. Hirsch FR, Gandara DR. PMID: 23782815.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    177. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul; 72(1):85-91. Iqbal S, Lenz HJ, Gandara DR, Shibata SI, Groshen S, Synold TW, Newman EM. PMID: 23712328; PMCID: PMC3779138.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    178. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol. 2013 May; 8(5):582-6. Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara DR. PMID: 23470290.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    179. Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem. 2013 May; 405(14):4953-8. Ruhaak LR, Taylor SL, Miyamoto S, Kelly K, Leiserowitz GS, Gandara D, Lebrilla CB, Kim K. PMID: 23525540; PMCID: PMC3640767.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    180. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol. 2013 Mar; 8(3):373-84. Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. PMID: 23370315.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    181. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin Lung Cancer. 2013 Jul; 14(4):351-5. Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara DR. PMID: 23415808; PMCID: PMC4567037.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    182. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013 Mar 10; 31(8):1039-49. Li T, Kung HJ, Mack PC, Gandara DR. PMID: 23401433; PMCID: PMC3589700.
      View in: PubMed   Mentions: 237     Fields:    Translation:Humans
    183. Non-small-cell lung cancer: then and now. J Clin Oncol. 2013 Mar 10; 31(8):981-3. Schiller JH, Gandara DR, Goss GD, Vokes EE. PMID: 23401450.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic Health
    184. Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1591-6. Mack PC, Gandara DR, Lara PN. PMID: 23253224.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    185. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. Cancer Res. 2012 Nov 01; 72(21):5556-65. Tuscano JM, Kato J, Pearson D, Xiong C, Newell L, Ma Y, Gandara DR, O'Donnell RT. PMID: 22986740.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    186. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL. PMID: 22831987; PMCID: PMC4319647.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    187. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012 Sep; 13(5):321-5. Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. PMID: 22677432; PMCID: PMC4049356.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    188. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. PMID: 22665541; PMCID: PMC3397785.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    189. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res. 2012 Aug 01; 18(15):4004-12. Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. PMID: 22592956; PMCID: PMC3409929.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    190. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. Cancer. 2012 Nov 01; 118(21):5358-65. Qi Y, Allen Ziegler KL, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA, Mandrekar SJ. PMID: 22434489; PMCID: PMC3481159.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    191. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8. Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR. PMID: 22198425; PMCID: PMC3288403.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    192. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012 Mar 15; 18(6):1726-34. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. PMID: 22307137; PMCID: PMC3306481.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    193. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. J Thorac Oncol. 2012 Jan; 7(1):34-9. Mahaffey CM, Mahaffey NC, Holland W, Zhang H, Gandara DR, Mack PC, Forman HJ. PMID: 22089114; PMCID: PMC3241903.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    194. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9. Sangha R, Davies AM, Lara PN, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. PMID: 21892109; PMCID: PMC3219834.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    195. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012 Mar; 69(3):835-43. Chao J, Synold TW, Morgan RJ, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. PMID: 22105720; PMCID: PMC3288125.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    196. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011 Nov; 6(11):1938-45. Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman M, Gandara DR. PMID: 21964533; PMCID: PMC3477852.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    197. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. Invest New Drugs. 2012 Oct; 30(5):2001-7. Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara PN. PMID: 22015991; PMCID: PMC4131984.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    198. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. PMID: 21716143; PMCID: PMC3220078.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    199. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011 Oct 15; 17(20):6574-81. Tarhini AA, Frankel P, Margolin KA, Christensen S, Ruel C, Shipe-Spotloe J, Gandara DR, Chen A, Kirkwood JM. PMID: 21880788; PMCID: PMC3196047.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    200. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. PMID: 21597387.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    201. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012 Jan; 69(1):185-94. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, Lara PN. PMID: 21644050; PMCID: PMC4562405.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    202. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol. 2011 Aug; 154(4):533-5. Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, Mohrbacher AF, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara DR. PMID: 21517811; PMCID: PMC3272081.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    203. A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct; 16(5):494-9. Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN. PMID: 21431345.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    204. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs. 2012 Jun; 30(3):1175-83. El-Khoueiry AB, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara D, Lenz HJ. PMID: 21424698; PMCID: PMC3745766.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    205. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15; 129(6):1425-34. Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. PMID: 21128223; PMCID: PMC3145006.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    206. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Curr Opin Oncol. 2011 Mar; 23(2):150-7. Rothschild SI, Gautschi O, Lara PN, Mack PC, Gandara DR. PMID: 21119513.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    207. Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol. 2011 Mar; 3(2):95-100. Semrad TJ, Gandara DR, Lara PN. PMID: 21789159; PMCID: PMC3126039.
      View in: PubMed   Mentions: 8  
    208. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol. 2011 Mar; 6(3):598-601. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. PMID: 21270668; PMCID: PMC3643692.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    209. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Mar 20; 29(9):1198-203. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. PMID: 21300924; PMCID: PMC3083875.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    210. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Mar 01; 29(7):909-16. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. PMID: 21282543; PMCID: PMC4668282.
      View in: PubMed   Mentions: 283     Fields:    Translation:HumansCTClinical Trials
    211. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. PMID: 21273177; PMCID: PMC3777729.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    212. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol. 2011 Jan; 6(1):139-47. Tsao MS, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maître A, Gandara D, Johnson DH, Rigas JR, Seymour L, Shepherd FA. PMID: 21107284; PMCID: PMC3033998.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    213. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol. 2011 Jan; 6(1):115-20. Blanchard EM, Moon J, Hesketh PJ, Kelly K, Wozniak AJ, Crowley J, Gandara D. PMID: 21107287; PMCID: PMC3075557.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    214. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):1933-8. Gandara DR, Grimminger P, Mack PC, Lara PN, Li T, Danenberg PV, Danenberg KD. PMID: 20975603.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    215. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010 Nov; 5(11):1835-40. Gitlitz BJ, Moon J, Glisson BS, Reimers HJ, Bury MJ, Floyd JD, Schulz TK, Sundaram PK, Ho C, Gandara DR. PMID: 20881645; PMCID: PMC3676180.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    216. Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung cancer. J Thorac Oncol. 2010 Nov; 5(11):1772-8. Suga JM, Nguyen DV, Mohammed SM, Brown M, Calhoun R, Yoneda K, Gandara DR, Lara PN. PMID: 20881638.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    217. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr; 30(2):741-8. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN, Gandara DR. PMID: 20967484; PMCID: PMC3277821.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    218. Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study. Invest New Drugs. 2012 Apr; 30(2):723-8. Morgan RJ, Leong L, Chow W, Gandara D, Frankel P, Garcia A, Lenz HJ, Doroshow JH. PMID: 20936324; PMCID: PMC3751394.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    219. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010 Oct 15; 16(20):4909-11. Hirsch FR, Wynes MW, Gandara DR, Bunn PA. PMID: 20926402.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    220. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010 Nov 01; 28(31):4747-54. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. PMID: 20921467; PMCID: PMC3020704.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    221. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010 Oct; 5(10):1706-13. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R, European EGFR Workshop Group. PMID: 20871269.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansPHPublic Health
    222. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer. 2010 Dec 15; 116(24):5710-5. Lara PN, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N, Gandara DR. PMID: 20737417; PMCID: PMC2994945.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    223. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010 Aug; 5(8):1279-84. Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Gandara DR. PMID: 20559150; PMCID: PMC2911495.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    224. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR. PMID: 20646741; PMCID: PMC2952720.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    225. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10; 28(11):1843-9. Pisters KM, Vallières E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. PMID: 20231678; PMCID: PMC2860367.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    226. [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi. 2010 Mar; 13(3):238-41. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. PMID: 20681067; PMCID: PMC6136060.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    227. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011 Aug; 29(4):680-7. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P, Khan I, Mack PC, Gandara DR, Davies AM. PMID: 20148348; PMCID: PMC4559347.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    228. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. Curr Drug Targets. 2010 Jan; 11(1):85-94. Li T, Lara PN, Mack PC, Perez-Soler R, Gandara DR. PMID: 19839922.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    229. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009 Dec; 4(12):1466-72. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN, Davies AM, Gandara DR. PMID: 19884861.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    230. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jan 01; 28(1):56-62. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, Belani CP. PMID: 19933908; PMCID: PMC2799233.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCTClinical Trials
    231. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010 Jan 01; 28(1):29-34. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao MS, Shepherd FA. PMID: 19933915; PMCID: PMC2799232.
      View in: PubMed   Mentions: 158     Fields:    Translation:HumansCTClinical Trials
    232. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer. 2009 Nov; 10(6):392-4. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. PMID: 19900855.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    233. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clin Lung Cancer. 2009 Nov; 10(6):395-404. Wakelee H, Loo BW, Kernstine KH, Putnam JB, Edelman MJ, Vokes EE, Schiller JH, Baas P, Saijo N, Adjei A, Goss G, Choy H, Gandara DR. PMID: 19900856.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    234. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 01; 28(4):614-9. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM, Schild SE, Zinner RG. PMID: 19841321; PMCID: PMC2815996.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    235. Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer. 2009 Sep; 10(5):322-30. Sangha R, Lara PN, Adjei AA, Baas P, Choy H, Gaspar LE, Goss G, Saijo N, Schiller JH, Vokes EE, Gandara DR. PMID: 19808190.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    236. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug 01; 374(9687):379-86. Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. PMID: 19632716; PMCID: PMC4407808.
      View in: PubMed   Mentions: 487     Fields:    Translation:HumansCTClinical Trials
    237. A decade of clinical lung cancer. Clin Lung Cancer. 2009 Jul; 10(4):216. Gandara DR, Simons J. PMID: 19632936.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    238. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol. 2009 Jul; 4(7):862-8. Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN, Perkins N, Gandara DR. PMID: 19494788.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    239. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009 Jul 20; 27(21):3540-6. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. PMID: 19470925; PMCID: PMC2717760.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    240. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer. 2009 May; 10(3):148-50. Gandara DR, Lara PN, Mack P, Scagliotti G. PMID: 19443333.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    241. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol. 2009 Jun 20; 27(18):3014-9. Le QT, Moon J, Redman M, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF, Gandara DR. PMID: 19364954; PMCID: PMC2702233.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    242. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20; 27(15):2530-5. Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. PMID: 19349543; PMCID: PMC2684855.
      View in: PubMed   Mentions: 193     Fields:    Translation:HumansCTClinical Trials
    243. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol. 2009 Apr; 4(4):448-54. Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O. PMID: 19240653; PMCID: PMC2716757.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    244. Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2009 Nov; 64(6):1149-55. Shibata SI, Doroshow JH, Frankel P, Synold TW, Yen Y, Gandara DR, Lenz HJ, Chow WA, Leong LA, Lim D, Margolin KA, Morgan RJ, Somlo G, Newman EM. PMID: 19322566; PMCID: PMC3046108.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    245. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009 May 01; 27(13):2163-9. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS. PMID: 19307510; PMCID: PMC2674003.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    246. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. PMID: 19396016; PMCID: PMC3225398.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    247. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol. 2009 Mar; 21(2):116-23. Sangha R, Lara PN, Mack PC, Gandara DR. PMID: 19532012.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    248. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 2009 Mar 20; 27(9):1401-4. Chen G, Huynh M, Fehrenbacher L, West H, Lara PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, Lau D. PMID: 19204194; PMCID: PMC2668551.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    249. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. PMID: 19169683.
      View in: PubMed   Mentions: 116     Fields:    Translation:HumansCTClinical Trials
    250. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009 Jan; 4(1):97-101. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D. PMID: 19096314; PMCID: PMC3263397.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    251. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. PMID: 19213668.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    252. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol. 2009 Jan; 4(1):87-92. Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR, Southwest Oncology Group. PMID: 19096312; PMCID: PMC3024911.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    253. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008 Nov 15; 14(22):7554-63. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ. PMID: 19010874; PMCID: PMC2586993.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    254. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008 Nov 01; 14(21):7138-42. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G. PMID: 18981013; PMCID: PMC3543872.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCTClinical Trials
    255. Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):346-51. Wakelee H, Kernstine K, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Goss G, Gaspar L, Gandara DR, Choy H, Putnam JB. PMID: 19073517.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    256. In Reply. Journal of Clinical Oncology. 2008 Oct 10; 26(29):4850-4851. Kelly KK, Redman RM, Gandara GD. .
      View in: Publisher Site   Mentions:
    257. Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol. 2008 Sep 10; 26(26):4236-8. Gandara DR, Lara PN, Natale R, Belani C. PMID: 18779609.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    258. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008 Oct 10; 26(29):4771-6. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR, SWOG. PMID: 18779603; PMCID: PMC2653139.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    259. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol. 2008 Sep; 3(9):1026-31. Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. PMID: 18758306; PMCID: PMC3523698.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    260. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res. 2008 Sep 01; 14(17):5565-70. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons DM. PMID: 18765549.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    261. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol. 2008 Aug; 31(4):317-22. Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, Shibata SI, Wagman LD, Wagman SD, Marx H, Chu PG, Longmate JA, Lenz HJ, Ramanathan RK, Belani CP, Gandara DR. PMID: 18845988.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    262. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med. 2008 Jul 28; 168(14):1541-9. Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN. PMID: 18663166.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    263. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. PMID: 18612151; PMCID: PMC3368372.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCTClinical Trials
    264. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun; 31(3):226-30. Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. PMID: 18525299.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    265. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S138-42. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA. PMID: 18520298.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    266. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20; 26(21):3543-51. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. PMID: 18506025.
      View in: PubMed   Mentions: 1161     Fields:    Translation:HumansCTClinical Trials
    267. Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy. Cancer Genomics Proteomics. 2008 May-Aug; 5(3-4):151-60. Xiao GG, Zhou BS, Somlo G, Portnow J, Juhasz A, Un F, Chew H, Gandara D, Yen Y. PMID: 18820369.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    268. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol. 2008 May; 3(5):545-55. Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. PMID: 18449013; PMCID: PMC3374724.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    269. Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity. Oncology (Williston Park). 2008 Apr 30; 22(5):511-6; discussion 516, 521-3. Calhoun R, Jablons D, Lau D, Gandara DR. PMID: 18533401.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    270. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008 Apr 01; 68(7):2250-8. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara DR, Mack PC, Kung HJ. PMID: 18381431.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    271. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20; 26(15):2450-6. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. PMID: 18378568.
      View in: PubMed   Mentions: 198     Fields:    Translation:HumansCTClinical Trials
    272. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008 Mar 15; 14(6):1639-48. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR. PMID: 18347165.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansAnimals
    273. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer. 2008 Mar; 9(2):85-91. Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara DR. PMID: 18501094.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    274. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008 Jan 20; 26(3):463-7. Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR, Southwest Oncology Group. PMID: 18202421.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    275. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution. Clin Lung Cancer. 2008; 9 Suppl 3:S90-1. Sangha R, Lara PN, Mack P, Gandara DR. PMID: 19419929.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    276. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol. 2008 Jan; 3(1):68-74. Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR. PMID: 18166843.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    277. Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions. Clin Lung Cancer. 2008; 9 Suppl 3:S129-38. Gautschi O, Mack PC, Davies AM, Jablons DM, Rosell R, Gandara DR. PMID: 19419927.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    278. Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):9-15. Wakelee H, Langer C, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd F, Choy H, Gandara DR. PMID: 18282352.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    279. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008 Jan 01; 26(1):76-82. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. PMID: 18165643.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansCTClinical Trials
    280. Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):35-8. Chen G, Huynh M, Chen A, Fehrenbacher L, Gandara D, Lau D. PMID: 18282356.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    281. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer. 2008 Jan 01; 112(1):212-9. Umutyan A, Chiechi C, Beckett LA, Paterniti DA, Turrell C, Gandara DR, Davis SW, Wun T, Chen MS, Lara PN. PMID: 18008353.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    282. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec; 2(12):1112-6. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. PMID: 18090584.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    283. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. PMID: 18272025.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    284. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 2007 Nov; 8(9):548-53. Mahaffey CM, Davies AM, Lara PN, Pryde B, Holland W, Mack PC, Gumerlock PH, Gandara DR. PMID: 18186959.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    285. Bevacizumab: optimal dose, schedule, and duration of therapy. Clin Lung Cancer. 2007 Nov; 8(9):522-3. Gandara DR, Sangha R, Davies AM. PMID: 18186957.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    286. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4647-51. Davies AM, Lara PN, Mack PC, Gandara DR. PMID: 17671158.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    287. Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer. Clin Lung Cancer. 2007 Jul; 8(7):420-4. Ho C, Davies A, Mack P, Gandara D. PMID: 17681094.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    288. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. J Thorac Oncol. 2007 Jul; 2(7 Suppl 3):S125-7. Gandara DR, Wakelee H, Calhoun R, Jablons D. PMID: 17603308.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    289. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007 Jul 01; 25(19):2747-54. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R. PMID: 17602080.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCTClinical Trials
    290. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007 Jun 15; 13(12):3660-6. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P, National Cancer Institute Organ Dysfunction Working Group. PMID: 17575231.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    291. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007 Jun 10; 25(17):2406-13. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC. PMID: 17557954.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCTClinical Trials
    292. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol. 2007 Jun; 2(6):526-30. Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara DR, SWOG. PMID: 17545848.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    293. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol. 2007 Jun; 2(6):537-43. Yoneda KY, Shelton DK, Beckett LA, Gandara DR. PMID: 17545850.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    294. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. J Thorac Oncol. 2007 Jun; 2(6):494-8. Hesketh PJ, Lilenbaum RC, Chansky K, Dowlati A, Graham P, Chapman RA, Crowley JJ, Gandara DR. PMID: 17545843.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    295. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR. PMID: 17508219.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    296. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007 Jul; 132(1):193-9. Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. PMID: 17505036.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    297. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718. J Thorac Oncol. 2007 May; 2(5):440-4. Hesketh PJ, Chansky K, Israel V, Grapski RT, Mekhail TM, Spiridonidis CH, Mills GM, Kelly K, Crowley JJ, Gandara DR. PMID: 17473660.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    298. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett. 2007 Sep 08; 254(2):265-73. Gautschi O, Huegli B, Ziegler A, Gugger M, Heighway J, Ratschiller D, Mack PC, Gumerlock PH, Kung HJ, Stahel RA, Gandara DR, Betticher DC. PMID: 17449174.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    299. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Invest New Drugs. 2007 Aug; 25(4):351-5. Davies AM, Ho C, Hesketh PJ, Beckett LA, Lara PN, Lau DH, Gandara DR. PMID: 17440682.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    300. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest. 2007 Apr-May; 25(3):182-8. Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF. PMID: 17530488.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    301. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease. Oncologist. 2007 Mar; 12(3):331-7. Wakelee H, Dubey S, Gandara D. PMID: 17405898.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    302. Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. Int J Gynecol Cancer. 2007 Mar-Apr; 17(2):373-8. Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. PMID: 17362315.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    303. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007 Apr; 18(4):752-60. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA. PMID: 17317677.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    304. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol. 2007 Feb; 2(2):153-7. Wang H, Ryu J, Gandara D, Bold RJ, Urayama S, Tanaka M, Goldberg Z, Follette D, Narayan S, Lau D. PMID: 17410032.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    305. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S61-7. Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN, Hirsch FR. PMID: 17382026.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    306. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007 Jan 20; 25(3):313-8. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. PMID: 17235046.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCTClinical Trials
    307. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. Clin Lung Cancer. 2006 Dec; 8 Suppl 1:S31-5. Yoneda KY, Hardin KA, Gandara DR, Shelton DK. PMID: 17239288.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    308. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 2006 Nov 20; 24(33):5242-6. Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR, SWOG S9712. PMID: 17114656.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    309. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6. Gandara DR, Aberle D, Lau D, Jett J, Akhurst T, Heelan R, Mulshine J, Berg C, Patz EF. PMID: 17409997.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansPHPublic Health
    310. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol. 2006 Nov; 1(9):996-1001. Lara PN, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, Gandara DR. PMID: 17409985.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    311. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. J Thorac Oncol. 2006 Nov; 1(9):991-5. Hesketh PJ, McCoy J, Dunphy FR, Bearden JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR. PMID: 17409984.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    312. A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. Cancer Chemother Pharmacol. 2007 Mar; 59(4):549-57. Shibata S, Chow W, Frankel P, Juhasz A, Leong L, Lim D, Margolin K, Morgan R, Newman E, Somlo G, Yen Y, Synold T, Gandara D, Lenz HJ, Doroshow J. PMID: 17051371.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    313. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer. 2006 Sep; 8(2):116-21. Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara PN, Kelly K, Crowley J, Livingston R. PMID: 17026812.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    314. Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin Lung Cancer. 2006 Sep; 8(2):93-8. Gautschi O, Mack PC, Davies AM, Lara PN, Gandara DR. PMID: 17026809.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    315. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer. 2006 Jul; 8(1):18-21. Wakelee HA, Schiller JH, Gandara DR. PMID: 16870041.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    316. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol. 2006 Jul; 1(6):537-44. Hesketh PJ, Chansky K, Lau DH, Doroshow JH, Moinpour CM, Chapman RA, Goodwin JW, Gross HM, Crowley JJ, Gandara DR. PMID: 17409914.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    317. Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line. J Clin Oncol. 2006 Jun 20; 24(18):2700-1. Gandara DR, Davies AM. PMID: 16682720.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    318. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006 May; 7(6):385-8. Davies AM, Ho C, Lara PN, Mack P, Gumerlock PH, Gandara DR. PMID: 16800963.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    319. Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. Clin Lung Cancer. 2006 May; 7 Suppl 4:S118-25. Ho C, Davies AM, Lara PN, Gandara DR. PMID: 16764752.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    320. Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep. 2006 May; 15(5):1299-304. Juhasz A, Vassilakos A, Chew HK, Gandara D, Yen Y. PMID: 16596201.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    321. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006 Apr 20; 24(12):1807-13. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR. PMID: 16622257.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    322. Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. Am J Clin Oncol. 2006 Apr; 29(2):116-22. Williamson SK, McCoy SA, Gandara DR, Dakhil SR, Yost KJ, Paradelo JC, Atkins JN, Blanke CD, Abbruzzese JL, Southwest Oncology Group (SWOG). PMID: 16601427.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    323. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2006 Mar 20; 24(9):1428-34. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara DR. PMID: 16549837.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    324. Bronchioloalveolar carcinoma: the "changing face of lung cancer". Clin Lung Cancer. 2006 Mar; 7(5):299. Gandara DR. PMID: 16640799.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    325. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. PMID: 16533781.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    326. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer. 2006 Mar; 7(5):353-6. Lara PN, Gandara DR, Natale RB. PMID: 16640809.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    327. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. Lara PN, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR. PMID: 17409841.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    328. North American Cooperative Group Research Efforts in Lung Cancer. . 2006 Jan 1; 451-461. Wakelee WH, Gandara GD. .
      View in: Publisher Site   Mentions:
    329. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005 Dec 20; 23(36):9097-104. Williamson SK, Crowley JJ, Lara PN, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR, Southwest Oncology Group Trial S0003. PMID: 16361616.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    330. Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol. 2005 Dec 20; 23(36):9282-9. Lara PN, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara DR, Wun T, Beckett LA, Chen MS. PMID: 16361626.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    331. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol. 2006 Jan 01; 24(1):141-4. Unger JM, Coltman CA, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS. PMID: 16330670.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    332. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S93-7. Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. PMID: 16384543.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    333. Treatment options for patients with advanced-stage non-small-cell lung cancer: who are the "elderly" and who are the "unfit"? Clin Lung Cancer. 2005 Nov; 7(3):154-5. Gandara DR, Hesketh P. PMID: 16354308.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    334. Bortezomib-based combinations in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S59-63. Davies AM, Lara PN, Mack PC, Gumerlock PH, Bold RJ, Gandara DR. PMID: 16250929.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    335. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S67-71. Lara PN, Bold RJ, Mack PC, Davies AM, Gumerlock PH, Gandara DR. PMID: 16250931.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    336. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer. 2005 Aug; 49(2):163-70. Mortenson MM, Schlieman MG, Virudachalam S, Lara PN, Gandara DG, Davies AM, Bold RJ. PMID: 16022909.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    337. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol. 2005 Sep 01; 23(25):5856-8. Gandara DR, Gumerlock PH. PMID: 16043825.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    338. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005 Oct 01; 23(28):6838-45. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, Gandara DR, Southwest Oncology Group. PMID: 15998906.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCTClinical Trials
    339. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s. Lynch TJ, Bogart JA, Curran WJ, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C. PMID: 16000599.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    340. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5057s-5062s. Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S. PMID: 16000614.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    341. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23; 352(25):2589-97. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F, National Cancer Institute of Canada Clinical Trials Group, National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. PMID: 15972865.
      View in: PubMed   Mentions: 559     Fields:    Translation:HumansCTClinical Trials
    342. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005 Jun 15; 11(12):4444-50. Lara PN, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR. PMID: 15958629.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    343. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005 May 01; 23(13):2955-61. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB, Gandara DR. PMID: 15860851.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    344. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol. 2005 Jul; 16(7):1076-80. West HL, Crowley JJ, Vance RB, Franklin WA, Livingston RB, Dakhil SR, Giguere JK, Rivkin SE, Kraut M, Chansky K, Gandara DR, Southwest Oncology Group. PMID: 15860488.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    345. Southwest Oncology Group: two decades of experience in non-small cell lung cancer. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S119-21. Turrisi AT, Crowley J, Albain K, Gaspar L, Gandara D. PMID: 16015548.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    346. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anticancer Drugs. 2005 Mar; 16(3):317-21. Lara PN, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR. PMID: 15711184.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    347. Computer-assisted image analysis of bronchioloalveolar carcinoma. Clin Lung Cancer. 2005 Mar; 6(5):281-6. Lau D, Seibert A, Gandara D, Laptalo L, Geraghty E, Coulon C. PMID: 15845178.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    348. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care. J Pain Symptom Manage. 2004 Dec; 28(6):548-56. Meyers FJ, Linder J, Beckett L, Christensen S, Blais J, Gandara DR. PMID: 15589080.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    349. Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells. Radiat Res. 2004 Dec; 162(6):623-34. Mack PC, Jones AA, Gustafsson MH, Gandara DR, Gumerlock PH, Goldberg Z. PMID: 15548112.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    350. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs. 2004 Oct; 15(9):871-5. Lau D, Guo L, Gandara D, Young LJ, Xue L. PMID: 15457127.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    351. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004 Sep; 6(2):102-7. Lara PN, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR. PMID: 15476595.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    352. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. PMID: 15530258.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    353. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res. 2004 Aug 15; 10(16):5418-24. Le QT, McCoy J, Williamson S, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides SD, Crowley JJ, Gandara DR, Southwest oncology group. PMID: 15328179.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    354. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res. 2004 Aug 01; 10(15):5022-6. Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR. PMID: 15297403.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    355. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s. Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. PMID: 15217958.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    356. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4205s-4209s. Gandara DR, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA. PMID: 15217959.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    357. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemother Pharmacol. 2004 Oct; 54(4):283-9. Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. PMID: 15184995.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    358. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann N Y Acad Sci. 2004 Jun; 1022:55-60. Kimura T, Holland WS, Kawaguchi T, Williamson SK, Chansky K, Crowley JJ, Doroshow JH, Lenz HJ, Gandara DR, Gumerlock PH. PMID: 15251940.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    359. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004 May 15; 100(10):2125-31. Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. PMID: 15139054.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCellsCTClinical Trials
    360. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit Rev Oncol Hematol. 2004 May; 50(2):111-9. Chen AY, Chou R, Shih SJ, Lau D, Gandara D. PMID: 15157660.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    361. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am. 2004 Apr; 18(2):373-85. Davies AM, Lara PN, Lau DH, Gandara DR. PMID: 15094177.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    362. Predictive molecular markers: has the time come for routine use in lung cancer? J Natl Compr Canc Netw. 2004 Mar; 2(2):125-31. Davies AM, Mack PC, Lara PN, Lau DH, Danenberg K, Gumerlock PH, Gandara DR. PMID: 19777702.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    363. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol. 2004 Feb; 31(1 Suppl 1):40-6. Lara PN, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, Gandara DR. PMID: 14981579.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    364. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 01; 10(3):924-8. Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. PMID: 14871968.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    365. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol. 2004 Jan 01; 22(1):127-32. Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR. PMID: 14701775.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    366. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan; 5(4):231-6. Lara PN, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, Doroshow JH, Gandara DR, California Cancer Consortium. PMID: 14967075.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    367. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003 Nov; 126(5):1597-602. Roberts PF, Straznicka M, Lara PN, Lau DH, Follette DM, Gandara DR, Benfield JR. PMID: 14666039.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    368. Developing targeted therapies for lung cancer. Clin Adv Hematol Oncol. 2003 Nov; 1(11):648-9, 690. Gandara DR. PMID: 16258461.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    369. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR, California Cancer Consortium. PMID: 14581348.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCellsCTClinical Trials
    370. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 01; 9(12):4356-62. Lara PN, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. PMID: 14555506.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    371. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S89-96. Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR. PMID: 12867067.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    372. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol. 2003 Aug; 30(4 Suppl 15):14-9. Doroshow JH, Synold TW, Gandara D, Mani S, Remick SC, Mulkerin D, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Takimoto CH, Ivy P. PMID: 14523790.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    373. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):11-6. Wild CA, Wang SE, Gandara DR, Lara PN, Meyers FJ, Tanaka M, Houston J, Lauder J, Lau DH. PMID: 12886868.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    374. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003 May 15; 21(10):2004-10. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN, Burris H, Gumerlock P, Kuebler JP, Bearden JD, Crowley J, Livingston R, Southwest Oncology Group. PMID: 12743155.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    375. Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother. 2003 Apr; 4(4):553-65. Davies AM, Lara PN, Mack PC, Gandara DR. PMID: 12667118.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    376. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol. 2003 Apr; 51(4):337-48. Mack PC, Gandara DR, Lau AH, Lara PN, Edelman MJ, Gumerlock PH. PMID: 12721762.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    377. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):197-9. Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, DeSanto J, Doyle LA. PMID: 12581573.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    378. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest. 2003; 21(1):7-13. Lim N, Lara PN, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara DR. PMID: 12643004.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    379. Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. J Clin Lab Anal. 2003; 17(5):184-94. Juhasz A, Frankel P, Cheng C, Rivera H, Vishwanath R, Chiu A, Margolin K, Yen Y, Newman EM, Synold T, Wilczynski S, Lenz HJ, Gandara D, Albain KS, Longmate J, Doroshow JH. PMID: 12938148; PMCID: PMC6808165.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    380. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest. 2003; 21(1):1-6. Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M. PMID: 12643003.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    381. Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S68-73. Davies AM, Gandara DR, Lara PN, Mack PC, Lau DH, Gumerlock PH. PMID: 14720340.
      View in: PubMed   Mentions: 5     Fields:    
    382. Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer. 2002 Dec; 38 Suppl 4:29-35. Vokes EE, Choy H, Gandara D, Mattson K. PMID: 12480192.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    383. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2002 Nov; 50(5):353-9. Yen Y, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D, Doroshow JH. PMID: 12439592.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    384. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15; 20(16):3454-60. Albain KS, Crowley JJ, Turrisi AT, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. PMID: 12177106.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    385. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002 Jul; 8(7):2286-91. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV, Rosell R. PMID: 12114432.
      View in: PubMed   Mentions: 188     Fields:    Translation:HumansCTClinical Trials
    386. Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer. Clin Lung Cancer. 2002 Jul; 4(1):47-51. Hesketh PJ, Nauman CJ, Hesketh AM, LaPointe J, Fogarty K, Oo TH, Lau DH, Edelman MJ, Gandara DR. PMID: 14653876.
      View in: PubMed   Mentions:    Fields:    
    387. Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 12):10-6. Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D. PMID: 12170446.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    388. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer. 2002 May 15; 94(10):2584-9. Lara PN, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, Tichauer G, Twardowski P, Doroshow JH, Gandara DR. PMID: 12173324.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    389. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel. Cancer. 2002 May 15; 94(10):2797-8; author reply 2798-9. De Castro J, Feliu J, Casado E, Ordoñez A, González Barón M. PMID: 12173351.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    390. Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3 Suppl 2:S42-8. Lara PN, Goldberg Z, Davies A, Lau DH, Gandara DR. PMID: 14720347.
      View in: PubMed   Mentions:    Fields:    
    391. Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res. 2002 Mar; 11(2):115-26. Moinpour CM, Lyons B, Grevstad PK, Lovato LC, Crowley J, Czaplicki K, Buckner ZM, Ganz PA, Kelly K, Gandara DR. PMID: 12018735.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    392. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst. 2002 Feb 20; 94(4):291-7. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, Gandara DR. PMID: 11854391.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    393. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol. 2002 Feb; 3(1):53-8. Lara PN, Lau DH, Gandara DR. PMID: 12057087.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    394. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol. 2002 Feb; 29(1 Suppl 4):102-9. Gandara DR, Lara PN, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH. PMID: 11894020.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    395. Phase I trial of edatrexate in advanced breast and other cancers. Cancer Invest. 2002; 20(4):473-9. Kuriakose P, Gandara DR, Perez EA. PMID: 12094542.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    396. Premedication strategy for weekly paclitaxel. Cancer Invest. 2002; 20(5-6):666-72. Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D. PMID: 12197222.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    397. Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer. 2001 Dec; 34 Suppl 3:S75-80. Gandara DR, Lara PN, Lau DH, Mack P, Gumerlock PH. PMID: 11740998.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    398. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Clin Cancer Res. 2001 Aug; 7(8):2325-9. Kelly K, Lovato L, Bunn PA, Livingston RB, Zangmeister J, Taylor SA, Roychowdhury D, Crowley JJ, Gandara DR, Southwest Oncology Group. PMID: 11489808.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    399. Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. Lung Cancer. 2001 Aug-Sep; 33(2-3):213-9. Thomas CR, Giroux DJ, Janaki LM, Turrisi AT, Crowley JJ, Taylor SA, McCracken JD, Shankir Giri PG, Gordon W, Livingston RB, Gandara DR. PMID: 11551416.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    400. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001 Jul 01; 19(13):3210-8. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. PMID: 11432888.
      View in: PubMed   Mentions: 242     Fields:    Translation:HumansCTClinical Trials
    401. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer. 2001 Jul 01; 92(1):146-52. Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D. PMID: 11443620.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    402. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2001 Jul; 48(1):22-8. Lara PN, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH. PMID: 11488520.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    403. Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel. Semin Oncol. 2001 Jun; 28(3 Suppl 9):26-32. Gandara DR, Lara PN, Goldberg Z, Lau DH. PMID: 11441412.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    404. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin Cancer Res. 2001 Jun; 7(6):1569-76. Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz HJ, Gandara D, Doroshow JH. PMID: 11410492.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    405. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001 Apr 18; 93(8):605-18. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK. PMID: 11309437.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    406. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. PMID: 11251003.
      View in: PubMed   Mentions: 248     Fields:    Translation:Humans
    407. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001 Mar 15; 19(6):1734-42. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA, Johnson BE. PMID: 11251004.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    408. Gemcitabine in combination with new platinum compounds: an update. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 6):13-7. Gandara DR, Edelman MJ, Lara PN, Lau DH. PMID: 11301843.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    409. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. 2001 Mar; 121(3):472-83. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D. PMID: 11241082.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    410. Neoadjuvant therapy for non-small cell lung cancer. Anticancer Drugs. 2001 Feb; 12 Suppl 1:S5-9. Gandara DR, Lara PN, Goldberg Z, Roberts P, Lau DH. PMID: 11340902.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    411. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol. 2001 Jan 15; 19(2):442-7. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J. PMID: 11208837.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    412. Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs. 2001; 19(4):335-40. Margolin K, Longmate J, Synold TW, Gandara DR, Weber J, Gonzalez R, Johansen MJ, Newman R, Baratta T, Doroshow JH. PMID: 11561695.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    413. A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413). Invest New Drugs. 2000 Aug; 18(3):269-73. Macdonald JS, Jacobson JL, Modiano M, Moore DF, Gandara DR, Schroder LE, Chapman RA. PMID: 10958597.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    414. Gemcitabine/carboplatin combination regimens: importance of dose schedule. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 4):26-30. Gandara DR, Lau DH, Lara PN, Edelman MJ. PMID: 10960942.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    415. Evolution of combined modality therapy for stage III non-small-cell lung cancer. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 5):35-41. Gandara DR, Edelman M, Lara P, Roberts P, Leigh B. PMID: 10981289.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    416. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000 Jun; 18(12):2354-62. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. PMID: 10856094.
      View in: PubMed   Mentions: 329     Fields:    Translation:HumansCTClinical Trials
    417. Sharing new approaches to translational research in non-small cell lung cancer. Oncologist. 2000; 5(6):514-9. O'Brate A, Tarón M, Gandara D, Rosell R. PMID: 11110605.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    418. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen. Support Care Cancer. 2000 Jan; 8(1):46-8. Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR. PMID: 10650897.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    419. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000 Jan; 18(1):131-5. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C. PMID: 10623703.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    420. Preoperative chemotherapy in stage III non-small cell lung cancer: long-term outcome. Lung Cancer. 1999 Oct; 26(1):3-6. Gandara DR, Leigh B, Vallieres E, Albain KS. PMID: 10574675.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    421. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin Cancer Res. 1999 Sep; 5(9):2596-604. Mack PC, Gandara DR, Bowen C, Edelman MJ, Paglieroni T, Schnier JB, Gelmann EP, Gumerlock PH. PMID: 10499638.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    422. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer. 1999 Aug 15; 86(4):684-8. Edelman MJ, Gandara DR, Meyers FJ, Ishii R, O'Mahony M, Uhrich M, Lauder I, Houston J, Gietzen DW. PMID: 10440697.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    423. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol. 1999 Aug; 17(8):2300-8. Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D. PMID: 10561291.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    424. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am. 1999 Jul-Aug; 5(4):237-41. Hesketh PJ, Crowley JJ, Burris HA, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF, Livingston RB, Gandara DR. PMID: 10439170.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    425. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol. 1999 Jun; 26(3 Suppl 10):3-7. Gandara DR, Edelman MJ, Lau D. PMID: 10437743.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    426. Summary of the proceedings of the United States--Japan lung cancer clinical trials summit: San Francisco, CA, 20-22 November, 1998. Lung Cancer. 1999 Jun; 24(3):181-91. Leigh BR, Gandara DR, Crowley JJ, Furuse K, Livingston RB, Fukushima M, Coltman CA. PMID: 10460006.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    427. ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. Am J Health Syst Pharm. 1999 04 15; 56(8):729-64. DCS. PMID: 10326616.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    428. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):117-20. Lau D, Ryu J, Gandara D, Morgan R, Doroshow J, Wilder R, Leigh B. PMID: 10210550.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    429. Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 4):12-8. Langer CJ, Gandara DR, Calvert P, Edelman MJ, Ozols RF. PMID: 10201516.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    430. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol. 1999; 44(6):461-8. Grunberg SM, Crowley J, Hande KR, Giroux D, Munshi N, Lau DH, Schroder LE, Zangmeister MH, Balcerzak SP, Hynes HE, Gandara DR. PMID: 10550566.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    431. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study. Cancer J Sci Am. 1999 Jan-Feb; 5(1):41-7. Sondak VK, Liu PY, Flaherty LE, Fletcher WS, Periman P, Gandara DR, Taylor SA, Balcerzak SP, Meyskens FL. PMID: 10188060.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    432. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol. 1998 Sep; 16(9):3078-81. Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, Fletcher WS, Lanier KS, Keiser WL, Livingston RB. PMID: 9738578.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    433. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998 Jul; 16(7):2459-65. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB. PMID: 9667264.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCTClinical Trials
    434. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer. 1998 May; 6(3):237-43. Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ. PMID: 9629876.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    435. Small cell lung cancer: current status of new chemotherapeutic agents. Crit Rev Oncol Hematol. 1998 Apr; 27(3):211-20. Edelman MJ, Gandara DR. PMID: 9649933.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    436. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol. 1998; 42(6):504-8. Lara PN, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. PMID: 9788578.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    437. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs. 1998; 16(1):69-75. Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F. PMID: 9740546.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    438. Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). Invest New Drugs. 1998; 16(2):171-3. Meyskens FL, Jacobson J, Nguyen B, Weiss GR, Gandara DR, MacDonald JS. PMID: 9848581.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    439. Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-106-S12-109. Lau DH, Ryu JK, Gandara DR, Morgan R, Doroshow J, Wilder R, Leigh B. PMID: 9331132.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    440. Chemoradiotherapy for poor-risk stage III non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-110-S12-112. Lau DH, Ryu JK, Gandara DR. PMID: 9331133.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    441. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone. Cancer J Sci Am. 1997 May-Jun; 3(3):180-3. Hesketh PJ, Gandara DR, Hesketh AM, Edelman M, Webber LM, McManus M, Hainsworth JD. PMID: 9161784.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    442. Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study. Int J Radiat Oncol Biol Phys. 1997 Apr 01; 38(1):157-61. Lau DH, Ryu JK, Gandara DR, Rosenthal SA. PMID: 9212018.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    443. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997 Jan; 15(1):103-9. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM. PMID: 8996130.
      View in: PubMed   Mentions: 133     Fields:    Translation:Humans
    444. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother Pharmacol. 1997; 41(1):75-8. Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. PMID: 9443617.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    445. Phase I study of paclitaxel with oral etoposide in advanced solid tumors. Cancer J Sci Am. 1996 Sep-Oct; 2(5):286-90. Perez EA, Coe T, Turrell C, Lau D, Campbell D, Gandara D. PMID: 9166546.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    446. Multimodality therapy in stage III non-small cell lung cancer. Ann Thorac Surg. 1996 May; 61(5):1564-72. Edelman MJ, Gandara DR, Roach M, Benfield JR. PMID: 8633990.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    447. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer. 1996 Mar; 4(2):141-6. Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, Martin LA, Cramer MB, Hahne WF. PMID: 8673351.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    448. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol. 1996; 37(5):385-93. Edelman MJ, Gandara DR. PMID: 8599859.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    449. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec; 13(12):2924-30. Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S, et al. PMID: 8523056.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    450. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. J Clin Oncol. 1995 Nov; 13(11):2835-41. Kaul S, Igwemezie LN, Stewart DJ, Fields SZ, Kosty M, Levithan N, Bukowski R, Gandara D, Goss G, O'Dwyer P, et al. PMID: 7595746.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    451. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol. 1995 Oct; 13(10):2606-12. Roach M, Gandara DR, Yuo HS, Swift PS, Kroll S, Shrieve DC, Wara WM, Margolis L, Phillips TL. PMID: 7595714.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    452. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995 Aug; 13(8):1880-92. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR, et al. PMID: 7636530.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansCTClinical Trials
    453. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May; 13(5):1242-8. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D. PMID: 7738628.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    454. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol. 1995 Feb; 13(2):490-6. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR, et al. PMID: 7844610.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    455. Concomitant and alternating radiation therapy (RT) and chemotherapy (CT) for inoperable, M0, non-small cell lung cancers (NSCLC): a consensus report. Lung Cancer. 1994 Nov; 11 Suppl 3:S5-8. Mirimanoff RO, Rubin P, Cox JD, Gandara D, Grunenwald D, Hazuka M, Jassem J, Komaki R, Mattson K, McDonald S, et al. PMID: 7704513.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    456. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. Semin Oncol. 1994 Jun; 21(3 Suppl 5):15-21. Perez EA, Gandara DR. PMID: 8042032.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    457. Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer. Semin Oncol. 1994 Jun; 21(3 Suppl 4):2-5. Perez EA, Gandara DR. PMID: 8209273.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    458. Phase I study of high-dose cisplatin, ifosfamide, and etoposide. Cancer Chemother Pharmacol. 1994; 34(4):331-4. Perez EA, Sowray PC, Gardner SL, Gandara DR. PMID: 8033300.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    459. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer. 1993 Aug 15; 72(4):1184-91. Albain KS, Crowley JJ, Hutchins L, Gandara D, O'Bryan RM, Von Hoff DD, Griffin B, Livingston RB. PMID: 8393365.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    460. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol. 1993 May; 11(5):873-8. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, et al. PMID: 8387576.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    461. Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer. 1993; 29A Suppl 1:S35-8. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ. PMID: 8427724.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    462. Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies. Cancer Chemother Pharmacol. 1993; 32(3):215-20. Valone FH, Gandara DR, Luce JA, Wall S, Perez EA, Braham N, George M, Letvak L. PMID: 8500227.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    463. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992 Dec; 10(12):1969-75. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR, et al. PMID: 1453211.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    464. Advances in the control of chemotherapy-induced emesis. Ann Oncol. 1992 Aug; 3 Suppl 3:47-50. Perez EA, Gandara DR. PMID: 1390317.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    465. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol. 1992 Aug; 19(4 Suppl 10):67-71. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, Finn AL, Hesketh PJ. PMID: 1387253.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    466. Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer. Cancer. 1991 Sep 01; 68(5):948-58. Carlson RW, Sikic BI, Gandara DR, Hendrickson CG, Wittlinger PS, Shields JA, Wong PP, White JE, Meakin CJ, McWhirter KM, et al. PMID: 1655219.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    467. Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother (1991). 1991 Jun; 10(3):207-13. Valone FH, Gandara DR, Deisseroth AB, Perez EA, Rayner A, Aronson FR, Luce J, Paradise C. PMID: 1651106.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    468. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst. 1991 May 01; 83(9):613-20. Hesketh PJ, Gandara DR. PMID: 1850806.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    469. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol. 1991 May; 9(5):721-8. Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, Gandara D, Hesketh P, Khojasteh A, Harker G, et al. PMID: 1826739.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    470. Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study. Int J Radiat Oncol Biol Phys. 1991 May; 20(5):1047-52. Gandara DR, Valone FH, Perez EA, Deisseroth AB, Roach M, Ahn DK, Phillips T. PMID: 1850719.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    471. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin Oncol. 1991 Feb; 18(1 Suppl 3):49-55. Gandara DR, Perez EA, Weibe V, De Gregorio MW. PMID: 1848372.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    472. Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study. J Immunother (1991). 1991 Feb; 10(1):57-62. Perez EA, Scudder SA, Meyers FA, Tanaka MS, Paradise C, Gandara DR. PMID: 2012799.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    473. Serotonin antagonists in the management of cisplatin-induced emesis. Semin Oncol. 1991 Feb; 18(1 Suppl 3):73-80. Perez EA, Hesketh PJ, Gandara DR. PMID: 2003230.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    474. Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer. 1991; 27 Suppl 1:S9-11; discussion S22. Gandara DR. PMID: 1831633.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    475. Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. Cancer. 1990 Sep 15; 66(6):1101-5. Khojasteh A, Sartiano G, Tapazoglou E, Lester E, Gandara D, Bernard S, Finn A. PMID: 2144788.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    476. Chemotherapy of metastatic testicular cancer: Current status and future prospects. World Journal of Urology. 1990 Mar 1; 8(1):20-26. Stanton ST, Perez PE, Gandara GD. .
      View in: Publisher Site   Mentions:
    477. Chromosomal abnormalities in non-Hodgkin's lymphoma. N Engl J Med. 1990 Feb 15; 322(7):475. Lawrence HJ, Gandara DR. PMID: 2300113.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    478. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol. 1990; 10(4):353-65. Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW. PMID: 2177606.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    479. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group. Cancer Chemother Pharmacol. 1990; 27(3):243-7. Gandara DR, Perez EA, Wold H, Caggiano V, Malec M, Ahn DK, Meyers F, Carlson RW. PMID: 2176134.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    480. Post-transfusion purpura and isoimmune neonatal thrombocytopenia in the same family. Am J Hematol. 1989 Nov; 32(3):235-6. Cobos E, Gandara DR, Geier LJ, Kirmani S. PMID: 2816919.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    481. Evaluation of cisplatin dose intensity: current status and future prospects. Anticancer Res. 1989 Jul-Aug; 9(4):1121-8. Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregorio M. PMID: 2683991.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    482. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol. 1989 Jun; 7(6):700-5. Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM. PMID: 2523957.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    483. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst. 1989 May 10; 81(10):790-4. Gandara DR, Wold H, Perez EA, Deisseroth AB, Doroshow J, Meyers F, McWhirter K, Hannigan J, De Gregorio MW. PMID: 2541260.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    484. Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother Pharmacol. 1989; 23(5):316-8. Lawrence HJ, Walsh D, Zapotowski KA, Denham A, Goodnight SH, Gandara DR. PMID: 2706738.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    485. Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. Cancer Chemother Pharmacol. 1989; 24(2):135-6. Gandara DR, Perez EA, Denham A, Wiebe VJ, DeGregorio MW. PMID: 2786459.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    486. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations. Cancer Chemother Pharmacol. 1989; 23(5):276-8. DeGregorio MW, Gandara DR, Holleran WM, Perez EA, King CC, Wold HG, Montine TJ, Borch RF. PMID: 2539912.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    487. Cisplatin and fluorouracil with or without sodium diethyldithiocarbamate rescue. J Clin Oncol. 1988 Nov; 6(11):1785-7. Gandara DR, Perez EA, DeGregorio MW, Borch R. PMID: 2846792.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    488. Differential diagnosis of monoclonal gammopathy. Med Clin North Am. 1988 Sep; 72(5):1155-67. Gandara DR, Mackenzie MR. PMID: 3137401.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    489. Conjugated estrogen for platelet dysfunction associated with liver disease. N Engl J Med. 1988 Jun 09; 318(23):1543. Perez EA, Tanaka M, Gandara DR. PMID: 2835682.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    490. Renal salt wasting in patients treated with cisplatin. Ann Intern Med. 1988 Jan; 108(1):21-5. Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA. PMID: 3337511.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    491. Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer. 1987 Dec 01; 60(11):2617-20. McLeod BF, Lawrence HJ, Smith DW, Vogt PJ, Gandara DR. PMID: 2445461.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    492. Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity. Cancer Treat Rep. 1987 Mar; 71(3):283-9. Benz C, Gandara D, Miller B, Drakes T, Monroe S, Wilbur B, DeGregorio M. PMID: 3493069.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    493. A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuridine alone. NCI Monogr. 1987; (5):175-7. Valone FH, Kohler M, Fisher K, Hannigan J, Flam M, Gandara D, Hendrickson C, Richman E, Yu KP. PMID: 2963230.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    494. Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria. Cancer Chemother Pharmacol. 1987; 19(2):165-8. Gandara DR, George CB, Ries CA, Koretz MM, Lewis JP. PMID: 3568275.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    495. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. J Clin Oncol. 1986 Dec; 4(12):1787-93. Gandara DR, DeGregorio MW, Wold H, Wilbur BJ, Kohler M, Lawrence HJ, Deisseroth AB, George CB. PMID: 3023557.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    496. Dose-limiting myelosuppression associated with high-dose cisplatin (200 mg/m2) in hypertonic saline. Cancer Treat Rep. 1986 Jun; 70(6):820-1. Gandara DR, Mansour R, Wold H, George C. PMID: 3731145.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    497. Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group. Semin Oncol. 1986 Mar; 13(1 Suppl 1):14-8. Gandara DR, Wold HG, Redmond J, Kohler M, Reynolds R, Wong P, Forsythe J, Fisher K, Lewis B. PMID: 3952517.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    498. Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer. 1984 Dec 01; 54(11):2360-2. George CB, Mansour RP, Redmond J, Gandara DR. PMID: 6594185.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    499. Phase II trial of 4'-epi-doxorubicin in metastatic melanoma. Cancer Treat Rep. 1984 Dec; 68(12):1509-10. Torti FM, Porzig KJ, Gandara DR, Volberding P, Mitchell E, Meyers FJ, Kohler M, Gribble M. PMID: 6595059.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    500. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol. 1984 Nov; 2(11):1192-9. Daniels JR, Chak LY, Sikic BI, Lockbaum P, Kohler M, Carter SK, Reynolds R, Bohnen R, Gandara D, Yu J. PMID: 6092554.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    501. Upper abdominal computerized tomography scanning in staging non-small cell lung carcinoma. Cancer. 1984 Oct 15; 54(8):1541-3. Chapman GS, Kumar D, Redmond J, Munderloh SH, Gandara DR. PMID: 6478395.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    502. Prolymphocytic leukemia. Serial responses to therapy. Cancer. 1984 Sep 15; 54(6):978-80. Swift JF, Wold HG, Gandara DR, Redmond J, George CB. PMID: 6590113.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    503. Morbidity in long-term survivors of small cell carcinoma of the lung. Cancer. 1984 Jul 01; 54(1):25-7. Volk SA, Mansour RF, Gandara DR, Redmond J. PMID: 6326998.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    504. Chronic lymphocytic leukemia with osteolytic bone lesions, hypercalcemia, and monoclonal protein. Am J Clin Pathol. 1983 May; 79(5):616-20. Redmond J, Stites DP, Beckstead JH, George CB, Casavant CH, Gandara DR. PMID: 6188367.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    505. Upper abdominal CT scanning in staging non-oat-cell lung carcinoma. N Engl J Med. 1982 Jul 15; 307(3):189. Chapman GS, Kumar D, Redmond J, Gandara DR. PMID: 7088061.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    506. A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts. Cancer Chemother Pharmacol. 1982; 9(1):10-2. Gandara DR, Ries CA, Schiff SA, George CB, Lewis JP, Koretz MM, Carter SK. PMID: 7139848.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    507. Persistence of periodic paralysis following treatment of thyrotoxicosis: case report. Mil Med. 1979 May; 144(5):337-8. Gandara DR, Fariss BL. PMID: 113707.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    508. Myoglobinuria associated with herpes-group viral infections. Arch Intern Med. 1978 Mar; 138(3):422-4. Schlesinger JJ, Gandara D, Bensch KG. PMID: 629637.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    David's Networks
    Concepts (850)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (95)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California